All-State Medicaid and CHIP Call
September 13, 2022
Agenda

• Monkeypox Update
• Eligibility and Enrollment Notice of Proposed Rulemaking Overview
• Open Mic Q and A
Medicaid & CHIP Coverage of Monkeypox Services

September 2022
Monkeypox was declared a public health emergency (PHE) by HHS Secretary Becerra on August 4, 2022.

At this time, there has been no declaration of a national emergency or disaster under the Stafford Act or the National Emergencies Act. Without a Presidential declaration, CMS is unable to grant section 1135 waivers for the Monkeypox PHE.

States can utilize existing flexibilities under the state plan, section 1915 waiver programs, section 1115 demonstration authority, or federal regulations, but new section 1135 waivers are not currently available for the Monkeypox PHE.

States must therefore follow the regular state plan amendment (SPA) submission timelines and process if they are seeking to make changes to their Medicaid State Plans in response to the Monkeypox PHE.

– Standard tribal consultation and public notice requirements related to SPA submission and effective dates apply.
Coverage of Monkeypox Testing

- In Medicaid,
  - **Monkeypox testing is covered** under the mandatory laboratory and X-ray services benefit.\(^1\),\(^2\),\(^3\)
  
  - With the declaration of the Monkeypox PHE, as described in 42 CFR 440.30(d), states may have flexibility as to the location in which lab tests may be administered and the requirement to first obtain an order from a physician or other licensed practitioner, provided that the flexibilities are intended to avoid monkeypox transmission. Testing must still be furnished by a CLIA-certified laboratory.

- In the Children’s Health Insurance Program (CHIP),
  - **Monkeypox testing can be covered** under the optional laboratory and x-ray services benefit.\(^4\)

---

\(^1\) 42 CFR 440.30.
\(^2\) CMS regulations require that the laboratory service be ordered and provided by or under the direction of a physician or other licensed practitioner; provided in an office or similar facility other than a hospital outpatient department or clinic; and furnished by a CLIA-certified laboratory (Note: public health laboratories and big commercial labs are generally CLIA-certified). The flexibilities available under 42 CFR 440.30(d) extend only to the first two of these requirements.
\(^3\) Medicaid alternative benefit plan (ABP) coverage must cover essential health benefits (EHB), which include laboratory services. 42 CFR 440.347. Testing services generally would be part of this coverage. The scope of testing coverage under an ABP may be different than for non-ABP Medicaid coverage, because ABPs must follow EHB rules to define laboratory service. This could vary state by state.
\(^4\) 42 CFR 457.402(h).
Coverage of Monkeypox Vaccination in Medicaid

- The Advisory Committee on Immunization Practices (ACIP) currently recommends monkeypox vaccination only for certain health care and laboratory workers who are at high risk of exposure. The Centers for Disease Control and Prevention (CDC) has also provided additional guidance on who might benefit from vaccination, including those with known or presumed exposure to monkeypox virus.¹

- States must cover for beneficiaries eligible for EPSDT any service that states could cover under section 1905(a), including a monkeypox vaccination, if the service is determined to be medically necessary for the beneficiary based on an individualized assessment and state medical necessity criteria. States may look to current ACIP recommendation criteria as the basis for determining medical necessity, at a minimum, and should also consider whether exposure or risk of exposure to the monkeypox virus would make vaccination medically necessary.

- States have the option to provide vaccination coverage for other Medicaid beneficiaries (i.e., those not eligible for coverage of the vaccination under EPSDT).

- Additionally, states that have opted to receive an extra percentage point of federal match for covering approved ACIP-recommended vaccinations for adults would be required to cover the monkeypox vaccination for those who meet the ACIP recommendation’s criteria, without cost sharing.²

¹ Information included on this slide may change if the ACIP updates their vaccination recommendations. If these recommendations change, CMS will provide updates to states.

² This was enacted under section 4106 of the ACA and is codified at section 1905(b) of the Social Security Act.
Coverage of Monkeypox Vaccination in CHIP and Additional Information

- CHIP coverage for the monkeypox vaccination is mandatory for individuals for whom ACIP recommends the vaccination.¹ For all other individuals, CHIP coverage is optional.

- Additional Vaccination Information
  - Jynneos, the preferred monkeypox vaccine, was approved by the U.S. Food and Drug Administration (FDA) in 2019 for those age 18 and older.² At this time, the vaccine is federally purchased and distributed at no cost to states or providers. Through the CDC provider agreement, no individual may be charged for the vaccine. However, an individual may be charged a fee for the administration of the vaccine. The monkeypox vaccine cannot be withheld if an individual does not have the means to pay the administration fee.
  
  - On August 9, 2022, FDA issued an emergency use authorization (EUA) permitting administration of Jynneos to those under age 18 years for the prevention of monkeypox disease among those at high risk for disease.

¹ 42 CFR 457.410(b)(2)
² While Jynneos is the preferred vaccine for monkeypox for individuals of all ages, there is an additional vaccine, ACAM2000, which the ACIP has also recommended for individuals at high risk of exposure. https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html
Coverage of Vaccine Administration and Counseling

- At this time, monkeypox vaccine is being federally purchased and therefore distributed at no cost to states and providers. Therefore, this slide focuses on vaccine administration.

- **Vaccine Administration:**
  - Can be covered under Medicaid’s preventive services benefit and may also be covered under other benefits such as physicians’ services and other licensed practitioner services.
  - CHIP can also cover vaccine administration, and this coverage is required for individuals for whom ACIP recommends the vaccination.

- **Standalone Vaccine Counseling:**
  - For people eligible for EPSDT, states must cover stand-alone vaccine counseling for all vaccinations covered under EPSDT. As discussed previously, this could include monkeypox vaccinations.
  - For separate CHIPS, coverage of standalone vaccine counseling is optional.¹

Medicaid Coverage of Monkeypox Therapies

- Currently there is no treatment approved by the FDA specifically for monkeypox virus infections, however antivirals developed for use in patients with smallpox may prove beneficial against monkeypox. Many of these drugs are available through the Strategic National Stockpile (SNS) for free.

- Some of these antiviral drugs may be covered outpatient drugs (CODs) under the Medicaid Drug Rebate Program (MDRP), but it will depend on whether the drug is being used for a medically accepted indication as that term is defined at section 1927(k)(6) of the Social Security Act. States should review the compendia listed in Section 1927(g)(1)(B)(i) of the SSA to determine whether the use of these drugs to treat monkeypox is supported by or approved for inclusion in the compendia.
  - If so, the drug may satisfy the definition of a COD, and if the manufacturer is in the MDRP (that is, has a Medicaid drug rebate agreement in effect), the drug would be eligible for FFP and rebates.
  - If the drug satisfies the definition of a COD but the manufacturer does not have a rebate agreement in effect, FFP and rebates are not available.
  - If the drug does not satisfy the definition of a COD, then the state may cover the drug as a prescribed drug and FFP would be available, but not rebates.
  - If an indication to treat monkeypox is eventually authorized under an FDA EUA for these or other FDA-approved drug, the drug could satisfy the definition of a COD and the state would be required to cover the drug and would be eligible to receive FFP and collect rebates if the manufacturer participates in the MDRP.

- States have the option to cover monkeypox antivirals in CHIP, but are not required to do so.
State Plan Requirements for Cost Sharing

- Cost sharing includes any copayment, coinsurance, deductible, or other similar charge, consistent with 42 CFR 447.51 and 457.10.

- States generally have flexibility to impose nominal Medicaid and CHIP\(^1\) cost sharing for monkeypox vaccinations,\(^2\) testing, and treatment. States are not required to impose cost sharing, and **CMS encourages states to remove or reduce cost sharing that might already be in the state plan by submitting a SPA.**

- Additionally, some populations and services must be exempted from Medicaid and CHIP cost sharing.
  - Populations exempted from Medicaid cost sharing include most Medicaid-eligible children under age 18, and American Indians/Alaska Natives who are currently receiving or have ever received an item or service furnished by an Indian health care provider or through referral under contract health services, and other populations described in 42 CFR 447.56. Populations exempted from CHIP cost sharing include American Indians/Alaska Natives.
  - Services exempted from Medicaid cost sharing include emergency services, family planning services, preventive services provided to children, pregnancy-related services and provider preventable services.

- Medicaid and CHIP premiums and cost sharing are subject to an aggregate limit of 5% of family income.

- In CHIP, for families under 150% of FPL, cost-sharing generally cannot exceed the nominal amounts permitted in Medicaid.

---

\(^1\)States may not impose cost-sharing in CHIP for immunizations recommended by ACIP pursuant to 42 CFR 457.520(b)(4).

\(^2\)Providers are subject to cost sharing limitations. See https://www.cdc.gov/poxvirus/monkeypox/clinicians/provider-agreement.html.
## Maximum Cost Sharing Based on Income

### Maximum Allowable Medicaid Cost Sharing for FY 2023

<table>
<thead>
<tr>
<th>Service</th>
<th>Beneficiaries with family income below 100% FPL</th>
<th>Beneficiaries with family income 101-150% FPL</th>
<th>Beneficiaries with family income above 150% FPL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Administration</td>
<td>$4.95</td>
<td>10% of cost agency pays</td>
<td>20% of cost agency pays</td>
</tr>
<tr>
<td>Testing</td>
<td>$4.95</td>
<td>10% of cost agency pays</td>
<td>20% of cost agency pays</td>
</tr>
<tr>
<td>Treatment: Drugs*</td>
<td>$4.95 (Outpatient services: $4.95 Inpatient stays: $92.00 for entire stay)</td>
<td>10% of cost agency pays for stay</td>
<td>20% of cost agency pays for stay</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10% of cost agency pays</td>
<td>20% of cost agency pays</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inpatient stays: $92.00 for entire stay</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Maximum cost sharing amounts shown are for commercially-available preferred drugs. Charges for non-preferred drugs may be higher.
SPAs for Coverage, Cost Sharing, and Reimbursement

- CMS strongly encourages states to evaluate current coverage, cost sharing, and reimbursement rates in their state plans to ensure sufficient coverage of monkeypox testing, treatment, and vaccine administration for Medicaid and CHIP beneficiaries. States should contact CMS with any coverage, cost sharing, or reimbursement SPA questions.

- States looking to provide coverage for any of the drugs used for monkeypox treatment should contact CMS for technical assistance.

- In Medicaid and CHIP, a SPA is needed if:
  - a state wants to reduce cost sharing associated with monkeypox testing, treatment, or vaccine administration, and/or
  - a state wants to increase payment for monkeypox testing, treatment, or vaccine administration in Medicaid.

- In Medicaid and CHIP, a SPA might not be needed if:
  - a state wants to expand coverage to include testing for monkeypox and the monkeypox vaccination.
Medicare Payment for Vaccine Administration and Testing

- **Vaccine Payment**
  - Part B covers medically necessary post-exposure administration of the monkeypox vaccination as a treatment for illness.
    - Paid using the generic vaccine administration codes (90460 and 90471) about $17 dollars depending on the setting, plus a geographic adjustment. No plan at this time for specific monkeypox vaccine administration codes.
  - Part D covers monkeypox vaccine administered *preventively, pre-exposure*, (not Part B).
    - Payment is determined by the beneficiary’s Part D plan.

- **Testing Payment**
  - Local MACs develop payment amounts for newly created clinical diagnostic laboratory test codes in their respective jurisdictions until Medicare establishes national payment rates on the Clinical Laboratory Fee Schedule
    - New AMA CPT® code to describe performance of polymerase chain reaction testing to detect the monkeypox virus (87593)
Streamlining Enrollment and Renewal Processes in Medicaid and CHIP (CMS-2421-P)

CMCS All-State Call

September 2022
Agenda

• Notice of Proposed Rulemaking (NPRM) Context
• Overview of NPRM Requirements
  – Streamline Application and Enrollment Processes
  – Improve Retention Rates at and between Renewals
  – Remove Access Barriers for Children
  – Enhance Program Integrity
• Implementation Timeframe
• Request for Comments
• Questions
Notice of Proposed Rulemaking

NPRM Publication Date: September 7, 2022

https://www.federalregister.gov/d/2022-18875

Comment Period: September 7 - November 7, 2022
Backdrop to NPRM

• Presidential Directives
  – Executive Order on Strengthening Medicaid and the Affordable Care Act (January 2021)
  – Executive Order on Continuing to Strengthen Americans’ Access to Affordable, Quality Health Coverage (April 2022)

• Affordable Care Act (ACA) Accomplishments
  – Streamlined application and renewal processes (e.g., increased reliance on electronic data sources and use of pre-populated forms)
  – Focus on MAGI-based populations

Important ACA simplifications not required for eligibility determinations and renewals based on age (65+) or having blindness or a disability
Enrollment Declines

- Following a period of steady growth attributed to the ACA, enrollment in Medicaid and CHIP declined from 2016 through 2019
- Evidence suggests the economy was the primary driver of this decline
- We also know that more restrictive State enrollment policies contribute to coverage disruptions and create churning

Program Integrity Concerns

- Medicaid and CHIP recordkeeping regulations are both outdated and lacking in specificity
- Insufficient documentation is a major driver of eligibility-related improper payments
NPRM Objectives

1. Streamline application and enrollment processes
2. Improve retention rates at and between renewals
3. Remove access barriers for children
4. Enhance program integrity
Objective 1: Streamline Application and Enrollment Processes
Facilitate Enrollment in the Medicare Savings Programs Using Part D Low-Income Subsidy Data
(42 CFR §§ 435.4, 435.601, 435.911, and 435.952)

• **Current**: Most individuals eligible for the full-subsidy Low-Income Subsidy (LIS) for Medicare Part D meet the eligibility requirements for a Medicare Savings Program (MSP) eligibility group, but over 1 million LIS recipients are not enrolled in the MSPs.

• **Proposed**: Streamline enrollment for individuals in LIS into the MSPs
  – Codify statutory requirement that states initiate MSP applications using LIS application data
  – Encourage states to adopt targeted income and resource disregards, to fully align LIS and MSP financial methodologies, including:
    • Dividend interest and income
    • Value of non-liquid resources
    • Burial funds
    • Cash value life insurance
Facilitate Enrollment in the Medicare Savings Programs Using Part D Low-Income Subsidy Data (§§ 435.4, 435.601, 435.911, and 435.952)

• **Proposed:** Streamline LIS enrollment into the MSPs (cont.)
  – Require states to accept Social Security Administration’s verified findings and deem full-subsidy LIS recipients as eligible for MSPs if income resource and methodologies are aligned
  – Accept self-attestation of income and resources not counted in determining LIS eligibility, with an option to conduct post-enrollment verification
  – Define family size in MSPs to be no less than the LIS definition: generally, the applicant, the applicant’s spouse, and certain other financially-dependent relatives living in the same household

*Facilitates alignment of LIS and MSP eligibility and enrollment and maximizes assistance with Medicare premiums and cost-sharing*
Automatically Enroll Certain Supplemental Security Income Recipients into the Qualified Medicare Beneficiary Group (§ 435.909)

• Current: Supplemental Security Income (SSI) beneficiaries are always financially eligible for the Qualified Medicare Beneficiary (QMB) MSP eligibility group, but nearly 500k are not enrolled

• Proposed: Require states to automatically enroll most SSI beneficiaries into the QMB group
  – Exception: Automatic enrollment would be optional for states that do not have a Part A buy-in agreement with CMS (“group payer states”)

Facilitates enrollment of individuals known to be eligible for the MSPs
Facilitate QMB Enrollment by Making the QMB Effective Date Earlier in Group Payer States (§ 406.21)

- **Current**: In group payer States, QMB coverage for individuals who enroll in conditional Part A during the Medicare general enrollment period (January through March) can begin as early as July 1 of the calendar year.

- **Proposed**: QMB coverage for individuals who enroll in conditional Part A during the general enrollment period in 2023 or later years could begin as early as the month after conditional Part A enrollment.

Maximizes assistance with Medicare premiums and cost-sharing and aligns with the Consolidated Appropriations Act of 2021
Facilitate Medically Needy Enrollment by Allowing Individuals to Deduct Prospective Medical Expenses (§ 435.831)

- **Current:** Medically needy individuals permitted to deduct from income their prospective institutional expenses, but *not* non-institutional expenses, in order to establish medically needy eligibility.

- **Proposed:** Enable medically needy individuals to deduct predictable non-institutional medical or remedial expenses, such as:
  - Cost of HCBS included in a section 1915(c), (i), (j), or (k) plan of care
  - Prescription drug expenses included in a patient's pharmacy profile

*Supports goal of rebalancing home and community-based services with institutional services for Medicaid beneficiaries*
Facilitate Medically Needy Enrollment by Allowing Individuals to Deduct Prospective Medical Expenses: Example

**Example Scenario:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual countable monthly income</td>
<td>$1,200</td>
</tr>
<tr>
<td>State's medically needy income level (MNIL)</td>
<td>$700</td>
</tr>
<tr>
<td>Difference between countable monthly income and MNIL</td>
<td>$500 ($1,200 - $700 = $500)</td>
</tr>
<tr>
<td>State budget period</td>
<td>3 months</td>
</tr>
<tr>
<td>Individual’s spenddown for budget period</td>
<td>$1,500 ($500 x 3 = $1,500)</td>
</tr>
</tbody>
</table>

**Current:**
- Individual is not eligible at start of budget period
- Medicaid eligibility starts only after $1,500 in expenses is incurred (partway into 3rd month of budget period)
- Individual experiences gap in coverage and cycles on and off Medicaid each budget period

**Proposed:**
- Individual is eligible at start of budget period using projected expenses at Medicaid rate ($600 x 3 = $1,800; $1,800 > $1,500)
- Individual does not experience gap in coverage caused by cycling on and off Medicaid each budget period
Apply Reasonable Compatibility Standards to Electronic Verification of Resource Information (§§ 435.952 and 435.940)

• **Current:** States are required to verify financial assets (for individuals subject to a resource test) using an Asset Verification System
  – Regulations do not explicitly address relationship of AVS to other documentation in verifying assets

• **Proposed:** Clarify that “reasonable compatibility” rules at § 435.952 apply to verification of resources
  – Information obtained from an electronic data source, such as AVS, considered reasonably compatible with attested information if both are either above or at or below applicable resource standard
  – States may apply different reasonable compatibility thresholds for income and resources
  – If attested asset information is not reasonably compatible with electronic data, state must seek additional information from the individual

*Supports streamlining enrollment for individuals applying on a non-MAGI basis and decreases burden for both States and beneficiaries*
Verification of Citizenship (§ 435.407*)

- **Current**: Individuals whose US citizenship is verified with a State’s vital statistics agency or DHS’ Systematic Alien Verification for Entitlements (SAVE) Program must also provide separate proof of identity.

- **Proposed**: Treat verification of citizenship with a State vital statistics agency or SAVE as stand-alone evidence of U.S. citizenship, not requiring separate proof of identity.

*Recognizes data match effectively verifies identity and reduces administrative burden on individuals and State Medicaid/CHIP agencies*

*This provision applies to CHIP through cross references at §§ 435.956 and 457.380*
Remove Requirement to Apply for Other Benefits (§§ 435.608)

• **Current:** Require all Medicaid applicants and beneficiaries, as a condition of eligibility, to apply for certain other benefits to which they are entitled (such as annuities, pensions, retirement, disability, and unemployment benefits)

  – Presents an unnecessary barrier to Medicaid eligibility, particularly when some of these benefits are not counted toward financial eligibility, such as when an individual is screened for an eligibility group to which an income test is not imposed or the particular benefits an individual might receive would not be counted under the financial methodology used to determine their eligibility

• **Proposed:** Eliminate requirement

  *Removes barriers to coverage*
Remove Optional Limitation on the Number of ROPs
(§§ 435.956 & 457.380)

- **Current**: States permitted to establish limits on the number of reasonable opportunity periods (ROP), if needed to ensure program integrity and approved by CMS
  - No State currently elects this option

- **Proposed**: Eliminate State option

*Ensures access to services for otherwise eligible individuals and better aligns with the statute*
Objective 2: Improve Retention Rates at and Between Renewals
Aligning MAGI and Non-MAGI Application and Renewal Requirements (§§ 435.907, 435.916)

• **Current**: For MAGI-based beneficiaries, in-person interviews may not be required at application and renewal, and States must provide at renewal:
  – **Renewal form prepopulated** with available information needed to renewal eligibility
  – Minimum of 30 calendar days to return prepopulated form
  – Minimum 90 day reconsideration period to reconsider eligibility without requiring a new application when coverage is terminated at renewal for failure to return form but individual subsequently returns completed form

  These policies are currently optional for non-MAGI beneficiaries

• **Proposed**: Require streamlined application and renewal processes for all Medicaid and CHIP beneficiaries, except as specifically allowed under statute*

  Facilitates continued enrollment of eligible individuals

*Section 1902(e)(8) of the Act allows States to renew eligibility for QMBs no more frequently than once every 6 months
Acting on Changes in Circumstances (§§ 435.919, 457.344)

• **Current:** Regulations are silent on expectations for processing redeterminations based on changes in circumstances

• **Proposed:**

1. Codify required steps for redetermining Medicaid and CHIP eligibility based on changes in circumstances for all beneficiaries:
   - Check available sources before requesting information from the beneficiary
   - Reach out to the beneficiary before taking adverse action
   - Maintain coverage in certain circumstances when a beneficiary does not respond

2. Require **minimum 30 calendar days** for all beneficiaries to respond to requests for information needed for a redetermination following a change in circumstances

3. Provide **90 day reconsideration period** for all beneficiaries terminated for failure to provide needed information without requiring a new application, similar to that currently provided at renewal

*Supports timely processing of redeterminations, improves continuity of coverage, and reduces churn.*
Required Actions When Beneficiaries Address May Have Changed (§§ 435.919 and 457.344)

• **Current:** Regulations do not prescribe proactive steps states must take when obtaining information indicating that a beneficiary’s address may have changed

• **Proposed:** Require proactive steps when beneficiary mail is returned or State obtains other information indicating a potential address change:
  
  – Leverage a standard set of data sources to obtain updated contact information (returned mail only)
  
  – Conduct outreach by mail, and via alternative modalities, to try to locate the beneficiary
  
  – *If still unable to locate the beneficiary,* require specific actions based on whether the beneficiary is in-state, out-of-state*, or whereabouts unknown

*Promotes continuity of coverage by reducing procedural terminations*

*If a State’s separate CHIP coverage is not available statewide, and the updated address lies outside geographic areas in which CHIP coverage is provided, State would follow the same steps proposed for out-of-state addresses*
Facilitating Transitions Between Medicaid and CHIP
(§§ 435.1200, 457.348, 457.350)

- **Current**: In States with a separate CHIP, transfer beneficiaries between Medicaid and CHIP when potential eligibility for the other program can be determined
  - When a State receives data indicating a change in eligibility and the beneficiary neither confirms nor denies the change, coverage may be terminated without a transition

- **Proposed**: In States with a separate CHIP:
  - The Medicaid agency will determine eligibility for CHIP
  - The CHIP agency will determine eligibility for Medicaid
  - Each agency will transition eligible individuals to the other agency and accept eligibility determinations made by the other agency
  - The agencies will issue a combined notice of eligibility

Prevents gaps in coverage for eligible children
Objective 3: Remove Access Barriers for Children
Current: States may impose up to a 90-day waiting period for enrollment in CHIP
- Most states have eliminated their waiting period
- In practice, states report that few children are subject to a waiting period after applying federally-required and state-specific exceptions

Proposed: Eliminate waiting periods in separate CHIPS
- Aligns with Medicaid and individual market Exchange plans
- Requires states to look to other monitoring strategies to prevent substitution of group health plan coverage
- Seeks comments on exception to permit 30 day waiting period if state demonstrates need to address crowd out

Improves access to care, such as primary and preventive care, that is particularly critical during childhood and adolescence & eliminates coverage gaps for eligible children
Remove Premium Lock-Out Periods in CHIP (§ 457.570)

- **Current**: States are permitted to apply a premium lock-out period for up to 90 days to prevent children in CHIP from enrolling in coverage if they have unpaid premiums or enrollment fees.

- **Proposed**: Remove premium lock-outs and encourage CHIPS to consider other mechanisms for addressing timely payment of premiums including:
  - Generating frequent reminder notices
  - Providing multiple and convenient options for paying premiums
  - Addressing language barriers to ensure families are knowledgeable about payment policies and procedures
  - Pursuing collection of past due premiums

**Improves continuity of care and more closely aligns CHIP and Medicaid state plan policies**
Prohibit Annual and Lifetime Benefit Limits in CHIP (§ 457.480)

• **Current**: Annual and lifetime limits are prohibited only for behavioral health benefits provided through a separate CHIP due to the Mental Health Parity Act of 1996 (MHPAEA)
  – States have already taken steps to remove limits on CHIP benefits, and no state has an aggregate lifetime limit on CHIP benefits

• **Proposed**: Prohibit annual and lifetime limits on any CHIP benefits

*Ensures continued access to coverage and aligns with Medicaid and the Marketplaces*
New Optional Medicaid Eligibility Group for Reasonable Classifications of Individuals Under Age 21 (§ 435.223)

• **Current:** Medicaid statute permits states to cover a reasonable classification of individuals under age 21 (i.e., “children”) within an optional statutory eligibility category
  – This authority is partly implemented at § 435.222, which generally authorizes states to cover an optional, MAGI-based eligibility group serving a reasonable classification of children

• **Proposed:** Establish a regulatory provision confirming States’ authority to cover non-MAGI-based Medicaid eligibility groups (i.e., groups that meet a MAGI exception in § 435.603(j)) serving one or more reasonable classifications of children
  – States would be authorized to apply disregards to such groups under the authority of section 1902(r)(2) of the Act

*Permits States to tailor optional coverage expansion to targeted groups of children based on specific state circumstances*
Objective 4: Enhance Program Integrity
Establish Maximum Timeframes for Redetermination of Eligibility
(§§ 435.912, 457.340)

• **Current:** States must determine eligibility at application within 45 days (90 days for applicants applying on the basis of disability), but regulations are silent on timeframes for processing redeterminations of eligibility at renewal and based on changes in circumstances

• **Proposed:** Establish specific timeframes for eligibility redeterminations
  – Timeframes are specific to different types of redeterminations (renewal vs. change in circumstance)
  – Longer timeframes provided for eligibility determinations on the basis of disability
  – Timeframes are extended when beneficiaries return requested information or documentation with less than 25 days remaining to provide sufficient time to check other bases of eligibility

*Establishes consistent standards for all States and allows required actions to occur more quickly*
Strengthen Recordkeeping Regulations in Medicaid and CHIP (§§ 431.17, 435.914, and 457.965)

• **Current**: Regulations on the maintenance of applicant and beneficiary case records are unclear and outdated
  – Record keeping deficiencies have been highlighted in recent Federal and State audits as well as Payment Error Rate Measurement (PERM) program reviews

• **Proposed**: Modernize States’ recordkeeping systems
  – Require records to be stored in an electronic format
  – Delineate the types of records that must be retained as part of each applicant and beneficiary case record
  – Establish a minimum record retention period for all such records extending through the period that the case is active, plus a minimum of 3 years thereafter

*Reduces auditing vulnerabilities by ensuring that eligibility and enrollment actions are properly documented*
In considering the timeframe for finalizing this NPRM, we:

– Recognize ongoing State work to unwind from the continuous enrollment condition effective during the COVID-19 public health emergency
– Seek to balance implementation of new options and requirements with the 12-14 month unwinding period
– Are considering an effective date of 30 – 60 days after final rule publication, with a separate date (or dates varying by provision) for compliance with finalized requirements

We seek comment on:

– Reasonable implementation timelines for each proposed provision
– An immediate effective date, with compliance no later than 12 months following
Submitting Public Comments

NPRM Publication Date: September 7, 2022
https://www.federalregister.gov/d/2022-18875

Comment Due Date: November 7, 2022

• Submit comments online at: http://www.regulations.gov
• Refer to file code CMS-2421-P when submitting comments
Request for Feedback

We need YOU to review and submit public comments!
Questions?